News

Exciting News | China’s Largest Semaglutide API Production Facility Passes U.S. FDA Inspection

From August 26 to August 30, 2024, JYMed’s peptide production facility, Hubei JX Bio-Pharmaceutical Co., Ltd., successfully passed an on-site inspection conducted by the U.S. Food and Drug Administration (FDA). The inspection covered key areas such as the quality system, production system, e... Read More

2024 CPHI Milan Pharmaceutical Exhibition Recap

01. Exhibition Overview On October 8th, the 2024 CPHI Worldwide Pharmaceutical Exhibition kicked off in Milan. As one of the most important annual events in the global pharmaceutical industry, it attracted participants from 166 countries and regions. With over 2,400 exhibitors and 62,000 professi... Read More

Exciting News | JYMed’s Liraglutide API Receives WC Certification

On October 12, 2024, JYMed’s Liraglutide API obtained the Written Confirmation (WC) certificate, marking a critical step toward the successful export of the API to the EU market. The WC (Written Confirmation) is a mandatory requirement for the export of APIs from non-EU countries to the... Read More

Exciting News: JYMed’s Leuprorelin Acetate Passes Drug Registration Inspection

Recently, JYMed Technology Co., Ltd. announced that Leuprorelin Acetate, produced by its subsidiary Hubei JX Bio-Pharmaceutical Co., Ltd., has successfully passed the drug registration inspection. Original Drug Market Overview Leuprorelin Acetate is an injectable medication used to trea... Read More

Congratutlation JYMed’s Tirzepatide Completes US-DMF Filing

JYMed Technology Co., Ltd. is pleased to announce that its product, Tirzepatide, has successfully completed the Drug Master File (DMF) registration with the U.S. FDA (DMF Number: 040115) and received the FDA’s Acknowledgement on August 2, 2024. Mass Production with Stable Quality ... Read More

JYMed Attends PCT 2024 in Shanghai

PCT2024 Personal Care Technology Summit & Exhibition is a highly influential event in the Asia-Pacific region, focusing on technology exchange and exhibitions in the personal care products industry.The forum will cover various aspects of the personal care industry, including technological in... Read More

JYMed Peptide Invites You to Attend the 2024 Korea In-cosmetics Ingredients Exhibition

  Location: Korea International Exhibition Center Date: July 24-26, 2024 Time: 10:00 AM – 5:00 PM Address: COEX Exhibition Center Hall C, 513 Yeongdong-daero, Gangnam-gu, Seoul, 06164   In-cosmetics is a leading international exhibition group in the personal care ingredien... Read More

New Regulation Bulletin

1. New FDA Registration Regulations for U.S. Cosmetics Cosmetics Without FDA Registration Will Be Banned from Sale.According to the Modernization of Cosmetics Regulation Act of 2022, signed by President Biden on December 29, 2022, all cosmetics exported to the United States must be FDA-registere... Read More

Spring Festival Holiday Notice

Please kindly be informed that our office will be closed from Feb. 4 to Feb.18 due to the Spring Festival. Any orders will be accepted but will not be processed until Feb.19, the first business day after the Spring Festival. Sorry for any inconvenience caused.     Read More

2023 The 88th API CHINA

Information about JYMed at 2023 API CHINA  【on-site】 Under the leadership of Vice General Manager Zhi Qin, Shenzhen JYMed Technology Co.,Ltd. (hereinafter referred to as JYMed)participated in this grand exhibition. JYMed showcased advantageous products Semaglutide, Liraglutide, Tirzepatide, O... Read More

Welcome to meet us at API exhibition at Qindao China JYMed stock: N4K32

Read More

JYMed got together with you at PCHi

After two years of expectation, the 2023 China International Cosmetics Personal and Home Care Raw Materials Exhibition (PCHi) had been held in the Guangzhou Canton Fair Complex on February 15-17, 2023. PCHi is an international trade show serving the global cosmetics, personal and home care produc... Read More

Semeglutide API of Shenzhen JYMed accepted by the first batch of domestic NMPA and Registered in US FDA (DMF No. 036009) with status “A”.

In May 2022, Shenzhen JYMed Technology Co., Ltd. (hereinafter referred to as JYMed peptide) submitted an application for the registration of semaglutide API to the US Food and Drug Administration (FDA) (DMF registration number: 036009), It has passed the integrity review, and the current status i... Read More

Copper Peptides: Skin and Hair Care Benefits and How to Use Them

We include products that we think our readers will find useful. We may earn a small commission if you make a purchase through a link on this page. This is our process. Peptides are naturally occurring amino acids that help produce collagen and elastin, the two connective tissues responsible for s... Read More

Ozempic (Semaglutide) Injection: Uses, Side Effects, Dosage

Erica Prouty, PharmD, is a professional pharmacist assisting patients with medication and pharmacy services in North Adams, Massachusetts. In non-human animal studies, semaglutide has been shown to cause C-cell thyroid tumors in rodents. However, it is unclear whether this risk extends to humans.... Read More

Derivatization of fatty acids in the discovery of peptide and protein drugs

Thank you for visiting Nature.com. The browser version you are using has limited CSS support. For the best experience, we recommend that you use an updated browser (or disable Compatibility Mode in Internet Explorer). In the meantime, to ensure continued support, we will render the site without s... Read More

Class I innovative drug of JYMed have made significant progress, Laipushutai is expected to become the first line of UC drugs.

On June 29, 2017, the development of Laipushutai, the class I innovative medicine with the cooperative development of JYMed and Guangzhou Linkhealth Medical Technology Co., Ltd., has made significant progress. The drug’s IND declaration has been accepted by the CFDA. JYMed and Guangzhou Lin... Read More

News & EventsThe Peptide Products Division in JYMed has flawlessly passed on-site inspection from FDA.

Warmly congratulate our Polypeptide Products Division for successfully passing the US FDA on-site inspection with “zero defects”! Passing the FDA on-site inspection with “zero defects” is a major event in our cGMP development history. It not only means that our API has obt... Read More